Immunology Partnerships

We’re partnering to bring cutting-edge technologies and assets to patients suffering from immuno-inflammatory conditions.
Miller, Atopic Dermatitis - Taiwan
Miller, Atopic Dermatitis - Taiwan

Beyond Dupixent®

We’re building on the success of Dupixent® in atopic dermatitis and asthma, developing new solutions for people with debilitating immuno-dermatological, rheumatic, respiratory, and gastrointestinal diseases.

Automatisation lab. mRNA equipment  - Marcy l'Etoile, France
Automatisation lab. mRNA equipment - Marcy l'Etoile, France

Scaling up innovation

We partner with companies that bring cutting-edge technologies and transformative assets in immuno-inflammation. We bring expertise in biological pathways, research-enabling technologies, proven precision-medicine approaches to clinical development, and robust commercial organization. 

Partnering success stories

Regeneron

This global collaboration produced Dupixent®, a novel biologic approved for atopic dermatitis, severe asthma, and eosinophilic esophagitis, and in development for a range of additional potential indications.

Kymera

In partnership with Kymera, we develop and commercialize first-in-class protein degrader therapies that target IRAK4 in patients with immuno-inflammatory diseases.

ImmuNext

We’re working on a CD40L monoclonal antibody (INX-021) initially developed by ImmuNext, as a treatment for autoimmune diseases including lupus and multiple sclerosis. 

Your partnering leads in Immunology

For more information, contact us at immunologybd@sanofi.com

Mark Dowling

Mark Dowling

Head of External Innovation, Immunology

Ulrich Wendt

Ulrich Wendt

Global Head of Business Development, Immunology